First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15134 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Naoya Ishibashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73‐year‐old female patient diagnosed with postoperative recurrence of lung carcinosarcoma. The resected tumor was diagnosed as lung carcinosarcoma, and genetic testing revealed the presence of the epidermal growth factor receptor (EGFR) exon21 L858R. Approximately 2 years postoperatively, the tumor recurred and the patient was treated with erlotinib plus ramucirumab, which were effective in controlling metastatic disease. Erlotinib plus ramucirumab is therefore a treatment option for EGFR mutation‐positive lung carcinosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
ORCID-Profile: Naoya Ishibashi
Zitieren
APA
Ishibashi, N., Tabata, T., Nonomura, R., Oshima, Y., Sasaki, T., Mitomo, H., Sugawara, T., & Sagawa, M. (2023). First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15134
Vancouver
Ishibashi N, Tabata T, Nonomura R, Oshima Y, Sasaki T, Mitomo H, et al. First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15134
BibTeX
@article{Ishibashi2023,
author = {Ishibashi, Naoya and Tabata, Toshiharu and Nonomura, Ryo and Oshima, Yutaka and Sasaki, Takanobu and Mitomo, Hideki and Sugawara, Takafumi and Sagawa, Motoyasu},
title = {First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15134}
}
EUVIMED